MYMDMyMD Pharmaceuticals, Inc.

Nasdaq mymd.com


$ 1.50 $ -0.05 (-3.35 %)    

Wednesday, 11-Sep-2024 15:59:51 EDT
QQQ $ 469.54 $ 0.00 (0 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 1.5077
$ 1.49 x 151
-- x --
-- - --
$ 1.50 - $ 21.90
12,930
na
4.2M
$ 2.10
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-19-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-01-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 05-18-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
17 08-14-2020 06-30-2020 10-Q
18 05-15-2020 03-31-2020 10-Q
19 03-25-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-14-2019 06-30-2019 10-Q
22 05-20-2019 03-31-2019 10-Q
23 04-01-2019 12-31-2018 10-K
24 11-14-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 07-13-2018 03-31-2018 10-Q
27 04-03-2018 12-31-2017 10-K
28 11-14-2017 09-30-2017 10-Q
29 08-14-2017 06-30-2017 10-Q
30 05-15-2017 03-31-2017 10-Q
31 04-11-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-12-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
36 11-13-2015 09-30-2015 10-Q
37 08-18-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 03-23-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

New name and stock symbol represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system

 mymd-pharmaceuticals-announces-corporate-rebranding-to-new-name-tnf-pharmaceuticals-to-begin-under-the-new-trading-symbol-tnfa-effective-july-24-2024

New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic systemCompany plans mid-stage cl...

 latest-key-hires--board-changes-in-cannabis-industry-canopy-growth-acreage-and-more

s Benzinga Cannabis Capital Conference returns to Chicago this Oct. 8-9 its 19th edition, gathering top CEOs, investors and inv...

Core News & Articles

Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to cr...

 why-tilray-brands-shares-are-trading-lower-by-around-22-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter esti...

 mymd-pharmaceuticals-filing-from-late-monday-shows-co-entered-omnibus-waiver-and-amendment-agreement-with-required-holders-under-previously-announced-securities-purchase-agreement

As previously disclosed, on February 21, 2023, MyMD Pharmaceuticals, Inc. (the "Company") entered into a Securities Pur...

 why-biophytis-shares-are-trading-higher-by-around-55-here-are-20-stocks-moving-premarket

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting FY23 results.

 mymd-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-requirement-for-continued-listing

MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company...

 mymd-pharmaceuticals-announces-1-for-30-reverse-stock-split-to-maintain-nasdaq-listing

Common Stock Will Begin Trading on Split-Adjusted Basis on February 15, 2024MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyM...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION